| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tanzania | 102 | 2024 | 1383 | 2.900 |
Why?
|
| HIV Infections | 116 | 2024 | 17165 | 2.750 |
Why?
|
| Data Interpretation, Statistical | 19 | 2020 | 2696 | 2.390 |
Why?
|
| Research Design | 26 | 2021 | 6180 | 2.360 |
Why?
|
| Models, Statistical | 22 | 2023 | 5075 | 2.360 |
Why?
|
| Public Health | 12 | 2021 | 2653 | 2.110 |
Why?
|
| Causality | 7 | 2024 | 1242 | 1.830 |
Why?
|
| Anti-HIV Agents | 38 | 2024 | 4491 | 1.670 |
Why?
|
| Likelihood Functions | 7 | 2021 | 987 | 1.610 |
Why?
|
| Proportional Hazards Models | 68 | 2021 | 12531 | 1.610 |
Why?
|
| Vitamins | 31 | 2020 | 1634 | 1.550 |
Why?
|
| Workplace | 6 | 2024 | 857 | 1.410 |
Why?
|
| Regression Analysis | 18 | 2019 | 6360 | 1.310 |
Why?
|
| Diet | 63 | 2024 | 8010 | 1.270 |
Why?
|
| Occupational Health Services | 2 | 2020 | 150 | 1.250 |
Why?
|
| Diet Surveys | 23 | 2018 | 1161 | 1.240 |
Why?
|
| Prenatal Care | 13 | 2023 | 1129 | 1.180 |
Why?
|
| Diet Records | 12 | 2018 | 427 | 1.150 |
Why?
|
| Vitamin A | 24 | 2020 | 613 | 1.140 |
Why?
|
| Infectious Disease Transmission, Vertical | 13 | 2019 | 1348 | 1.130 |
Why?
|
| Food Services | 2 | 2021 | 205 | 1.110 |
Why?
|
| Meta-Analysis as Topic | 5 | 2018 | 1376 | 1.080 |
Why?
|
| Nurses | 29 | 2020 | 2467 | 1.060 |
Why?
|
| Risk Reduction Behavior | 6 | 2020 | 1109 | 1.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 26 | 2020 | 1894 | 1.020 |
Why?
|
| Pregnancy Complications, Infectious | 29 | 2018 | 2125 | 1.000 |
Why?
|
| Infant Mortality | 10 | 2019 | 757 | 0.930 |
Why?
|
| Humans | 504 | 2024 | 760621 | 0.920 |
Why?
|
| Bisexuality | 8 | 2018 | 274 | 0.920 |
Why?
|
| Female | 397 | 2024 | 391270 | 0.910 |
Why?
|
| Adult | 309 | 2024 | 219994 | 0.900 |
Why?
|
| Homosexuality, Female | 7 | 2012 | 159 | 0.900 |
Why?
|
| Anemia, Iron-Deficiency | 10 | 2022 | 368 | 0.890 |
Why?
|
| Colorectal Neoplasms | 20 | 2021 | 6853 | 0.890 |
Why?
|
| Carotenoids | 16 | 2013 | 620 | 0.850 |
Why?
|
| Validation Studies as Topic | 5 | 2018 | 162 | 0.850 |
Why?
|
| Risk Factors | 183 | 2022 | 74359 | 0.840 |
Why?
|
| Child Mortality | 4 | 2019 | 205 | 0.840 |
Why?
|
| Alcohol Drinking | 26 | 2020 | 4013 | 0.840 |
Why?
|
| Breast Neoplasms | 49 | 2024 | 21025 | 0.830 |
Why?
|
| Food Preferences | 4 | 2021 | 399 | 0.830 |
Why?
|
| Dietary Supplements | 38 | 2022 | 3392 | 0.820 |
Why?
|
| Randomized Controlled Trials as Topic | 17 | 2022 | 10344 | 0.820 |
Why?
|
| Sexual Behavior | 8 | 2019 | 2086 | 0.790 |
Why?
|
| Premenopause | 23 | 2017 | 1038 | 0.750 |
Why?
|
| Poverty Areas | 1 | 2022 | 264 | 0.750 |
Why?
|
| Incidence | 79 | 2022 | 21392 | 0.740 |
Why?
|
| Endometriosis | 12 | 2018 | 874 | 0.730 |
Why?
|
| Anemia | 12 | 2022 | 1511 | 0.730 |
Why?
|
| Risk | 40 | 2017 | 9631 | 0.720 |
Why?
|
| Food Service, Hospital | 1 | 2020 | 18 | 0.710 |
Why?
|
| Energy Intake | 16 | 2018 | 2129 | 0.710 |
Why?
|
| Survival Analysis | 13 | 2020 | 10182 | 0.710 |
Why?
|
| Prospective Studies | 150 | 2023 | 54303 | 0.700 |
Why?
|
| Fruit | 14 | 2024 | 1160 | 0.690 |
Why?
|
| Nepal | 8 | 2023 | 301 | 0.680 |
Why?
|
| Environmental Exposure | 15 | 2023 | 4412 | 0.670 |
Why?
|
| Confidence Intervals | 19 | 2019 | 2932 | 0.670 |
Why?
|
| Hypertension | 17 | 2022 | 8594 | 0.650 |
Why?
|
| Linear Models | 16 | 2023 | 5877 | 0.640 |
Why?
|
| Multivariate Analysis | 43 | 2018 | 12159 | 0.640 |
Why?
|
| Dietary Proteins | 12 | 2017 | 949 | 0.640 |
Why?
|
| Contact Tracing | 3 | 2022 | 268 | 0.640 |
Why?
|
| Anti-Retroviral Agents | 9 | 2020 | 1779 | 0.630 |
Why?
|
| Prediabetic State | 2 | 2024 | 550 | 0.620 |
Why?
|
| Middle Aged | 218 | 2024 | 220352 | 0.620 |
Why?
|
| Risk Assessment | 42 | 2020 | 24123 | 0.610 |
Why?
|
| Epidemiologic Methods | 6 | 2017 | 1343 | 0.600 |
Why?
|
| Personnel, Hospital | 1 | 2020 | 285 | 0.590 |
Why?
|
| Computer Simulation | 17 | 2023 | 6218 | 0.590 |
Why?
|
| Unsafe Sex | 1 | 2019 | 213 | 0.580 |
Why?
|
| Program Evaluation | 5 | 2023 | 2493 | 0.570 |
Why?
|
| Male | 233 | 2024 | 359744 | 0.570 |
Why?
|
| Diabetes Mellitus, Type 2 | 24 | 2022 | 12293 | 0.570 |
Why?
|
| Colonic Neoplasms | 9 | 2022 | 2526 | 0.560 |
Why?
|
| Vegetables | 13 | 2016 | 1196 | 0.560 |
Why?
|
| Feeding Behavior | 19 | 2024 | 3185 | 0.560 |
Why?
|
| Pregnancy | 80 | 2023 | 29749 | 0.550 |
Why?
|
| Cardiovascular Diseases | 22 | 2024 | 15757 | 0.550 |
Why?
|
| CD4 Lymphocyte Count | 27 | 2020 | 2569 | 0.550 |
Why?
|
| Diet Therapy | 1 | 2017 | 151 | 0.550 |
Why?
|
| Cohort Studies | 112 | 2022 | 41335 | 0.540 |
Why?
|
| Iron | 8 | 2022 | 1786 | 0.540 |
Why?
|
| Early Detection of Cancer | 6 | 2023 | 3202 | 0.540 |
Why?
|
| Health Behavior | 6 | 2024 | 2622 | 0.540 |
Why?
|
| Prevalence | 38 | 2022 | 15687 | 0.530 |
Why?
|
| Biological Factors | 2 | 2016 | 157 | 0.530 |
Why?
|
| Uterine Cervical Dysplasia | 3 | 2019 | 384 | 0.530 |
Why?
|
| Malnutrition | 7 | 2018 | 640 | 0.530 |
Why?
|
| Body Mass Index | 57 | 2018 | 12914 | 0.530 |
Why?
|
| Primary Prevention | 3 | 2020 | 1207 | 0.520 |
Why?
|
| Breast Feeding | 12 | 2017 | 1355 | 0.520 |
Why?
|
| Ascorbic Acid | 13 | 2014 | 655 | 0.520 |
Why?
|
| Mass Screening | 9 | 2023 | 5423 | 0.520 |
Why?
|
| Coronary Disease | 16 | 2018 | 5990 | 0.520 |
Why?
|
| Odds Ratio | 25 | 2019 | 9716 | 0.510 |
Why?
|
| Life Style | 16 | 2024 | 3896 | 0.510 |
Why?
|
| Epidemiologic Studies | 5 | 2023 | 670 | 0.500 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 1 | 2015 | 28 | 0.500 |
Why?
|
| Epidemiologic Research Design | 2 | 2018 | 368 | 0.500 |
Why?
|
| Nutritional Status | 17 | 2024 | 1607 | 0.500 |
Why?
|
| Tuberculosis, Pulmonary | 6 | 2022 | 831 | 0.500 |
Why?
|
| Dietary Fiber | 11 | 2012 | 760 | 0.490 |
Why?
|
| Uterine Cervical Neoplasms | 5 | 2023 | 2003 | 0.490 |
Why?
|
| Lost to Follow-Up | 1 | 2015 | 123 | 0.490 |
Why?
|
| Diabetes Mellitus | 6 | 2022 | 5889 | 0.490 |
Why?
|
| Vitamin D | 13 | 2020 | 3291 | 0.480 |
Why?
|
| Biometry | 2 | 2011 | 559 | 0.480 |
Why?
|
| Anthropometry | 10 | 2018 | 1348 | 0.480 |
Why?
|
| Respiratory Sounds | 4 | 2015 | 697 | 0.480 |
Why?
|
| Cluster Analysis | 5 | 2021 | 2698 | 0.480 |
Why?
|
| Pregnancy Outcome | 18 | 2018 | 2907 | 0.480 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2021 | 1200 | 0.470 |
Why?
|
| Air Pollution, Indoor | 5 | 2020 | 893 | 0.470 |
Why?
|
| Sample Size | 6 | 2021 | 840 | 0.470 |
Why?
|
| Vitamin E | 14 | 2014 | 872 | 0.470 |
Why?
|
| Dietary Fats | 12 | 2017 | 1992 | 0.470 |
Why?
|
| Substance Abuse, Intravenous | 5 | 2024 | 530 | 0.460 |
Why?
|
| Dietary Carbohydrates | 12 | 2019 | 892 | 0.460 |
Why?
|
| Infant Nutritional Physiological Phenomena | 5 | 2017 | 351 | 0.450 |
Why?
|
| Micronutrients | 9 | 2020 | 381 | 0.450 |
Why?
|
| United States | 87 | 2024 | 72461 | 0.450 |
Why?
|
| Calcium, Dietary | 7 | 2015 | 531 | 0.450 |
Why?
|
| Occupational Diseases | 4 | 2017 | 1486 | 0.450 |
Why?
|
| Patient Education as Topic | 4 | 2020 | 2315 | 0.440 |
Why?
|
| Weight Gain | 13 | 2016 | 2347 | 0.440 |
Why?
|
| Longitudinal Studies | 33 | 2023 | 14495 | 0.430 |
Why?
|
| Follow-Up Studies | 62 | 2024 | 39261 | 0.430 |
Why?
|
| Cross-Sectional Studies | 37 | 2023 | 25942 | 0.430 |
Why?
|
| Fatty Acids | 7 | 2020 | 1804 | 0.420 |
Why?
|
| International Cooperation | 1 | 2019 | 1433 | 0.420 |
Why?
|
| Zinc | 5 | 2020 | 689 | 0.420 |
Why?
|
| Young Adult | 63 | 2024 | 58741 | 0.410 |
Why?
|
| Selenium | 8 | 2012 | 416 | 0.410 |
Why?
|
| Folic Acid | 11 | 2017 | 1309 | 0.410 |
Why?
|
| HIV-1 | 20 | 2017 | 6849 | 0.410 |
Why?
|
| Calibration | 6 | 2024 | 816 | 0.400 |
Why?
|
| Potassium, Dietary | 4 | 2017 | 104 | 0.400 |
Why?
|
| Air Pollutants | 7 | 2023 | 2844 | 0.400 |
Why?
|
| Exercise | 17 | 2024 | 5787 | 0.390 |
Why?
|
| Nonlinear Dynamics | 2 | 2011 | 494 | 0.390 |
Why?
|
| Interpersonal Relations | 1 | 2019 | 1428 | 0.390 |
Why?
|
| Growth Disorders | 6 | 2016 | 653 | 0.380 |
Why?
|
| Infant, Low Birth Weight | 9 | 2018 | 859 | 0.380 |
Why?
|
| Phospholipids | 5 | 2015 | 789 | 0.380 |
Why?
|
| Psychology, Experimental | 1 | 2010 | 5 | 0.370 |
Why?
|
| Models, Theoretical | 3 | 2017 | 3562 | 0.370 |
Why?
|
| Clinical Protocols | 6 | 2020 | 1440 | 0.370 |
Why?
|
| Magnesium | 4 | 2015 | 810 | 0.370 |
Why?
|
| alpha-Linolenic Acid | 4 | 2014 | 144 | 0.370 |
Why?
|
| Respiratory Tract Infections | 7 | 2020 | 1007 | 0.370 |
Why?
|
| Coffee | 6 | 2018 | 582 | 0.360 |
Why?
|
| Sex Factors | 12 | 2018 | 10547 | 0.360 |
Why?
|
| Bayes Theorem | 2 | 2021 | 2326 | 0.360 |
Why?
|
| Viral Load | 17 | 2020 | 3322 | 0.360 |
Why?
|
| Hypercholesterolemia | 7 | 2022 | 1155 | 0.360 |
Why?
|
| Vehicle Emissions | 4 | 2016 | 653 | 0.350 |
Why?
|
| Overweight | 11 | 2018 | 2421 | 0.340 |
Why?
|
| Aged | 116 | 2024 | 169152 | 0.340 |
Why?
|
| Hypertension, Pregnancy-Induced | 3 | 2022 | 518 | 0.340 |
Why?
|
| Endotoxins | 4 | 2006 | 521 | 0.330 |
Why?
|
| Human papillomavirus 18 | 2 | 2020 | 125 | 0.330 |
Why?
|
| Sex Hormone-Binding Globulin | 6 | 2016 | 546 | 0.330 |
Why?
|
| Medication Adherence | 5 | 2024 | 2165 | 0.330 |
Why?
|
| Meat | 7 | 2016 | 584 | 0.330 |
Why?
|
| Infant, Newborn | 36 | 2023 | 26181 | 0.330 |
Why?
|
| Birth Weight | 8 | 2015 | 2097 | 0.320 |
Why?
|
| Obesity | 22 | 2018 | 12922 | 0.320 |
Why?
|
| Maternal Health Services | 3 | 2019 | 455 | 0.310 |
Why?
|
| Smoking | 32 | 2014 | 9073 | 0.310 |
Why?
|
| Community Health Services | 4 | 2019 | 654 | 0.310 |
Why?
|
| Hemoglobins | 10 | 2020 | 1521 | 0.310 |
Why?
|
| Thyroid Neoplasms | 1 | 2022 | 2332 | 0.310 |
Why?
|
| HIV Seronegativity | 3 | 2012 | 208 | 0.310 |
Why?
|
| HIV Wasting Syndrome | 6 | 2014 | 97 | 0.310 |
Why?
|
| Self Report | 8 | 2019 | 3711 | 0.310 |
Why?
|
| Diarrhea | 7 | 2017 | 1319 | 0.310 |
Why?
|
| Blood Pressure | 6 | 2024 | 8525 | 0.310 |
Why?
|
| Human papillomavirus 16 | 2 | 2020 | 265 | 0.310 |
Why?
|
| Age Factors | 20 | 2021 | 18416 | 0.300 |
Why?
|
| Tuberculosis | 6 | 2022 | 2001 | 0.300 |
Why?
|
| Focus Groups | 4 | 2024 | 1378 | 0.300 |
Why?
|
| Nutrition Assessment | 8 | 2018 | 727 | 0.300 |
Why?
|
| Epidemiology | 1 | 2010 | 278 | 0.300 |
Why?
|
| HIV Seropositivity | 5 | 2017 | 955 | 0.300 |
Why?
|
| Health Knowledge, Attitudes, Practice | 9 | 2023 | 3986 | 0.300 |
Why?
|
| Dust | 4 | 2006 | 483 | 0.300 |
Why?
|
| India | 10 | 2022 | 2336 | 0.300 |
Why?
|
| Wasting Syndrome | 4 | 2014 | 98 | 0.290 |
Why?
|
| Patients | 1 | 2014 | 906 | 0.290 |
Why?
|
| Erythrocyte Membrane | 2 | 2020 | 439 | 0.290 |
Why?
|
| Gonadal Steroid Hormones | 4 | 2016 | 701 | 0.290 |
Why?
|
| Morbidity | 7 | 2020 | 1765 | 0.290 |
Why?
|
| Methylmercury Compounds | 3 | 2013 | 102 | 0.290 |
Why?
|
| Time Factors | 25 | 2020 | 40165 | 0.290 |
Why?
|
| Pregnancy Complications, Hematologic | 4 | 2019 | 177 | 0.290 |
Why?
|
| Vitamin B Complex | 5 | 2014 | 297 | 0.280 |
Why?
|
| Women's Health | 8 | 2016 | 2056 | 0.280 |
Why?
|
| Nutritive Value | 4 | 2015 | 349 | 0.280 |
Why?
|
| Reproducibility of Results | 21 | 2023 | 20080 | 0.280 |
Why?
|
| Adolescent | 55 | 2024 | 87810 | 0.280 |
Why?
|
| Case-Control Studies | 46 | 2020 | 22053 | 0.280 |
Why?
|
| Cooking | 3 | 2020 | 311 | 0.280 |
Why?
|
| Conjunctivitis | 1 | 2008 | 155 | 0.280 |
Why?
|
| Prolactin | 3 | 2016 | 621 | 0.270 |
Why?
|
| Occupational Exposure | 7 | 2016 | 1809 | 0.270 |
Why?
|
| Child Nutritional Physiological Phenomena | 3 | 2015 | 295 | 0.270 |
Why?
|
| Air Pollution | 5 | 2023 | 2317 | 0.270 |
Why?
|
| Thinness | 5 | 2016 | 491 | 0.270 |
Why?
|
| Dairy Products | 6 | 2010 | 494 | 0.260 |
Why?
|
| Nurse Clinicians | 2 | 2008 | 30 | 0.260 |
Why?
|
| Tea | 4 | 2011 | 284 | 0.260 |
Why?
|
| Cause of Death | 6 | 2022 | 3725 | 0.260 |
Why?
|
| Uncertainty | 2 | 2014 | 754 | 0.260 |
Why?
|
| Africa South of the Sahara | 4 | 2021 | 742 | 0.260 |
Why?
|
| Epidemiologic Measurements | 1 | 2005 | 22 | 0.260 |
Why?
|
| Double-Blind Method | 22 | 2020 | 12427 | 0.260 |
Why?
|
| Infant | 36 | 2021 | 36060 | 0.250 |
Why?
|
| Nutrition Policy | 6 | 2016 | 470 | 0.250 |
Why?
|
| Mental Recall | 5 | 2017 | 1206 | 0.250 |
Why?
|
| Respiration Disorders | 2 | 2006 | 368 | 0.250 |
Why?
|
| Particulate Matter | 6 | 2023 | 2559 | 0.250 |
Why?
|
| Condoms | 3 | 2019 | 315 | 0.250 |
Why?
|
| Heterosexuality | 5 | 2012 | 294 | 0.250 |
Why?
|
| Counseling | 4 | 2020 | 1548 | 0.240 |
Why?
|
| Socioeconomic Factors | 15 | 2020 | 7806 | 0.240 |
Why?
|
| Health Education | 2 | 2024 | 1049 | 0.240 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 3388 | 0.240 |
Why?
|
| Health Facilities | 3 | 2020 | 578 | 0.240 |
Why?
|
| Aspirin | 7 | 2016 | 3364 | 0.240 |
Why?
|
| Milk | 7 | 2011 | 443 | 0.240 |
Why?
|
| Lung Neoplasms | 9 | 2022 | 13262 | 0.240 |
Why?
|
| Nitrogen Dioxide | 2 | 2015 | 512 | 0.240 |
Why?
|
| Blood Glucose | 10 | 2020 | 6381 | 0.240 |
Why?
|
| Contraception Behavior | 2 | 2019 | 180 | 0.240 |
Why?
|
| Mortality | 6 | 2016 | 2916 | 0.230 |
Why?
|
| Antioxidants | 8 | 2010 | 1667 | 0.230 |
Why?
|
| Pregnancy in Adolescence | 2 | 2018 | 162 | 0.230 |
Why?
|
| Malaria | 6 | 2020 | 1226 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2017 | 10827 | 0.230 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 5325 | 0.230 |
Why?
|
| Motor Activity | 5 | 2015 | 2687 | 0.230 |
Why?
|
| Stroke | 10 | 2018 | 9962 | 0.230 |
Why?
|
| Cholecalciferol | 2 | 2020 | 550 | 0.230 |
Why?
|
| Housing | 3 | 2006 | 665 | 0.230 |
Why?
|
| Health Personnel | 9 | 2024 | 3310 | 0.220 |
Why?
|
| Health Services Accessibility | 3 | 2020 | 5397 | 0.220 |
Why?
|
| Premature Birth | 6 | 2015 | 1771 | 0.220 |
Why?
|
| Food Handling | 2 | 2015 | 155 | 0.220 |
Why?
|
| Health Services Research | 3 | 2022 | 1810 | 0.220 |
Why?
|
| Models, Genetic | 4 | 2021 | 3442 | 0.220 |
Why?
|
| Melanoma | 1 | 2022 | 5697 | 0.220 |
Why?
|
| Body Weight | 16 | 2015 | 4611 | 0.210 |
Why?
|
| beta Carotene | 5 | 2012 | 524 | 0.210 |
Why?
|
| Reproductive History | 2 | 2016 | 210 | 0.210 |
Why?
|
| Seafood | 4 | 2016 | 390 | 0.210 |
Why?
|
| Motor Vehicles | 3 | 2016 | 281 | 0.210 |
Why?
|
| Nutrition Surveys | 6 | 2018 | 1725 | 0.210 |
Why?
|
| Mercury | 3 | 2012 | 290 | 0.210 |
Why?
|
| Child Development Disorders, Pervasive | 3 | 2012 | 599 | 0.210 |
Why?
|
| Complementary Therapies | 2 | 2023 | 486 | 0.210 |
Why?
|
| Mammography | 2 | 2016 | 2427 | 0.200 |
Why?
|
| Kenya | 3 | 2020 | 749 | 0.200 |
Why?
|
| Nails | 4 | 2013 | 295 | 0.200 |
Why?
|
| Pregnancy Complications | 7 | 2015 | 2942 | 0.200 |
Why?
|
| Health Promotion | 4 | 2024 | 2206 | 0.200 |
Why?
|
| Drug Users | 1 | 2023 | 132 | 0.200 |
Why?
|
| Research | 1 | 2010 | 1974 | 0.200 |
Why?
|
| Peer Group | 2 | 2024 | 674 | 0.200 |
Why?
|
| Body Size | 3 | 2013 | 462 | 0.200 |
Why?
|
| Trace Elements | 3 | 2015 | 196 | 0.200 |
Why?
|
| Mexico | 2 | 2021 | 760 | 0.190 |
Why?
|
| Receptors, Progesterone | 4 | 2020 | 1130 | 0.190 |
Why?
|
| Eggs | 3 | 2016 | 183 | 0.190 |
Why?
|
| Risk-Taking | 2 | 2024 | 998 | 0.190 |
Why?
|
| Analysis of Variance | 7 | 2019 | 6238 | 0.190 |
Why?
|
| Flour | 2 | 2019 | 21 | 0.190 |
Why?
|
| Mental Disorders | 2 | 2019 | 6796 | 0.190 |
Why?
|
| Child, Preschool | 25 | 2021 | 42063 | 0.190 |
Why?
|
| Body Height | 8 | 2016 | 1570 | 0.190 |
Why?
|
| Perinatal Care | 3 | 2014 | 242 | 0.190 |
Why?
|
| Myocardial Infarction | 11 | 2020 | 11891 | 0.190 |
Why?
|
| Self-Help Groups | 1 | 2022 | 189 | 0.190 |
Why?
|
| Urban Health | 4 | 2013 | 533 | 0.190 |
Why?
|
| Nutritional Physiological Phenomena | 5 | 2005 | 363 | 0.190 |
Why?
|
| Infant, Small for Gestational Age | 4 | 2015 | 460 | 0.190 |
Why?
|
| Carbonated Beverages | 3 | 2011 | 209 | 0.190 |
Why?
|
| Software | 4 | 2016 | 4419 | 0.190 |
Why?
|
| Spouse Abuse | 2 | 2012 | 179 | 0.190 |
Why?
|
| Vitamin A Deficiency | 3 | 2017 | 88 | 0.190 |
Why?
|
| Disease Susceptibility | 2 | 2019 | 1791 | 0.180 |
Why?
|
| Fatty Acids, Omega-3 | 6 | 2013 | 1387 | 0.180 |
Why?
|
| Health Surveys | 9 | 2017 | 4063 | 0.180 |
Why?
|
| Contraceptives, Oral, Hormonal | 2 | 2013 | 190 | 0.180 |
Why?
|
| Adiposity | 3 | 2017 | 1858 | 0.180 |
Why?
|
| Health Status | 5 | 2011 | 4081 | 0.180 |
Why?
|
| Inflammation Mediators | 2 | 2020 | 1881 | 0.180 |
Why?
|
| Herpesvirus 4, Human | 4 | 2010 | 1075 | 0.180 |
Why?
|
| Leiomyoma | 4 | 2007 | 654 | 0.180 |
Why?
|
| Pregnancy Complications, Parasitic | 3 | 2017 | 61 | 0.170 |
Why?
|
| Work Schedule Tolerance | 3 | 2011 | 551 | 0.170 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2016 | 1126 | 0.170 |
Why?
|
| Disclosure | 1 | 2006 | 738 | 0.170 |
Why?
|
| Child Development | 5 | 2014 | 2285 | 0.170 |
Why?
|
| Domestic Violence | 2 | 2012 | 181 | 0.170 |
Why?
|
| Nomograms | 1 | 2022 | 238 | 0.170 |
Why?
|
| Multicenter Studies as Topic | 3 | 2022 | 1722 | 0.170 |
Why?
|
| Fetal Growth Retardation | 2 | 2014 | 579 | 0.170 |
Why?
|
| Adipose Tissue | 9 | 2010 | 3301 | 0.170 |
Why?
|
| Statistics as Topic | 7 | 2017 | 2362 | 0.170 |
Why?
|
| Public Sector | 2 | 2020 | 265 | 0.170 |
Why?
|
| Calcitriol | 2 | 2014 | 297 | 0.170 |
Why?
|
| Epstein-Barr Virus Infections | 4 | 2010 | 608 | 0.170 |
Why?
|
| Protein-Energy Malnutrition | 2 | 2013 | 188 | 0.170 |
Why?
|
| Abortion, Spontaneous | 3 | 2011 | 530 | 0.170 |
Why?
|
| Rural Population | 3 | 2020 | 2268 | 0.170 |
Why?
|
| Zea mays | 1 | 2019 | 112 | 0.170 |
Why?
|
| Guideline Adherence | 2 | 2020 | 2283 | 0.160 |
Why?
|
| Insurance Coverage | 2 | 2021 | 1939 | 0.160 |
Why?
|
| Postmenopause | 6 | 2016 | 2509 | 0.160 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2011 | 1375 | 0.160 |
Why?
|
| Pancreatic Neoplasms | 6 | 2012 | 5351 | 0.160 |
Why?
|
| Hematologic Tests | 1 | 2020 | 238 | 0.160 |
Why?
|
| Community-Institutional Relations | 1 | 2020 | 208 | 0.160 |
Why?
|
| Diet, Vegetarian | 2 | 2017 | 180 | 0.160 |
Why?
|
| Antitubercular Agents | 3 | 2017 | 1373 | 0.160 |
Why?
|
| Logistic Models | 21 | 2018 | 13314 | 0.160 |
Why?
|
| Environment | 2 | 2019 | 1118 | 0.160 |
Why?
|
| Child Abuse, Sexual | 2 | 2012 | 392 | 0.160 |
Why?
|
| Treatment Outcome | 24 | 2021 | 65017 | 0.160 |
Why?
|
| Ki-67 Antigen | 1 | 2020 | 631 | 0.160 |
Why?
|
| Midwifery | 1 | 2020 | 122 | 0.160 |
Why?
|
| Depression | 5 | 2021 | 8044 | 0.150 |
Why?
|
| Papillomavirus Infections | 2 | 2020 | 1607 | 0.150 |
Why?
|
| Receptors, Estrogen | 4 | 2020 | 2210 | 0.150 |
Why?
|
| Carcinoma, Renal Cell | 6 | 2009 | 3218 | 0.150 |
Why?
|
| Menarche | 6 | 2016 | 529 | 0.150 |
Why?
|
| Malaria, Falciparum | 3 | 2017 | 1076 | 0.150 |
Why?
|
| Child Abuse | 3 | 2012 | 1067 | 0.150 |
Why?
|
| Cost Sharing | 1 | 2021 | 410 | 0.150 |
Why?
|
| Artemisinins | 1 | 2020 | 218 | 0.150 |
Why?
|
| Energy Metabolism | 4 | 2011 | 2869 | 0.150 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 2 | 2014 | 389 | 0.150 |
Why?
|
| Child | 29 | 2022 | 79806 | 0.150 |
Why?
|
| Nuclear Family | 1 | 2019 | 313 | 0.150 |
Why?
|
| Survival Rate | 6 | 2022 | 12808 | 0.150 |
Why?
|
| Latent Tuberculosis | 1 | 2020 | 224 | 0.140 |
Why?
|
| Eating | 5 | 2017 | 1539 | 0.140 |
Why?
|
| Weight Loss | 6 | 2012 | 2686 | 0.140 |
Why?
|
| C-Peptide | 3 | 2011 | 433 | 0.140 |
Why?
|
| Postnatal Care | 2 | 2016 | 260 | 0.140 |
Why?
|
| Chronic Disease | 7 | 2021 | 9287 | 0.140 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2002 | 592 | 0.140 |
Why?
|
| Acne Vulgaris | 3 | 2008 | 355 | 0.140 |
Why?
|
| Fishes | 5 | 2013 | 601 | 0.140 |
Why?
|
| Menstruation Disturbances | 2 | 2011 | 143 | 0.140 |
Why?
|
| Arm | 2 | 2018 | 583 | 0.140 |
Why?
|
| Beverages | 5 | 2015 | 820 | 0.140 |
Why?
|
| Prenatal Exposure Delayed Effects | 4 | 2015 | 2496 | 0.140 |
Why?
|
| Forecasting | 2 | 2017 | 2932 | 0.140 |
Why?
|
| Proto-Oncogene Proteins B-raf | 5 | 2013 | 2053 | 0.140 |
Why?
|
| Folic Acid Deficiency | 1 | 2017 | 117 | 0.140 |
Why?
|
| Oncogene Proteins | 1 | 2020 | 719 | 0.140 |
Why?
|
| Waist-Hip Ratio | 2 | 2015 | 516 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2022 | 3529 | 0.140 |
Why?
|
| Age of Onset | 3 | 2021 | 3301 | 0.140 |
Why?
|
| Iron, Dietary | 3 | 2012 | 148 | 0.140 |
Why?
|
| Cystatins | 2 | 2008 | 55 | 0.140 |
Why?
|
| CpG Islands | 3 | 2012 | 1221 | 0.140 |
Why?
|
| Antibodies, Viral | 5 | 2017 | 3143 | 0.130 |
Why?
|
| Body Composition | 8 | 2011 | 2419 | 0.130 |
Why?
|
| Drinking | 2 | 2011 | 199 | 0.130 |
Why?
|
| Uterine Neoplasms | 4 | 2007 | 1439 | 0.130 |
Why?
|
| Food, Fortified | 1 | 2017 | 189 | 0.130 |
Why?
|
| Religion | 1 | 2019 | 376 | 0.130 |
Why?
|
| Quality of Health Care | 4 | 2020 | 4360 | 0.130 |
Why?
|
| Homosexuality | 1 | 2016 | 261 | 0.130 |
Why?
|
| Epidemics | 2 | 2019 | 510 | 0.130 |
Why?
|
| Glycemic Index | 4 | 2019 | 396 | 0.130 |
Why?
|
| Dyslipidemias | 3 | 2013 | 895 | 0.130 |
Why?
|
| Adult Survivors of Child Abuse | 2 | 2010 | 284 | 0.130 |
Why?
|
| Nigeria | 5 | 2020 | 762 | 0.130 |
Why?
|
| Treatment Failure | 4 | 2020 | 2648 | 0.130 |
Why?
|
| Laparoscopy | 5 | 2017 | 2147 | 0.130 |
Why?
|
| Nuts | 1 | 2018 | 263 | 0.130 |
Why?
|
| Self Disclosure | 1 | 2016 | 249 | 0.130 |
Why?
|
| Tobacco Smoke Pollution | 3 | 2011 | 812 | 0.130 |
Why?
|
| Anticarcinogenic Agents | 2 | 2010 | 249 | 0.130 |
Why?
|
| Long Interspersed Nucleotide Elements | 3 | 2012 | 330 | 0.130 |
Why?
|
| Anemia, Hypochromic | 2 | 2012 | 63 | 0.130 |
Why?
|
| Intrauterine Devices | 1 | 2016 | 114 | 0.130 |
Why?
|
| Developing Countries | 6 | 2013 | 2868 | 0.120 |
Why?
|
| Poverty | 3 | 2019 | 2695 | 0.120 |
Why?
|
| Fetal Death | 3 | 2007 | 434 | 0.120 |
Why?
|
| Neural Tube Defects | 1 | 2017 | 254 | 0.120 |
Why?
|
| Area Under Curve | 3 | 2015 | 1636 | 0.120 |
Why?
|
| Antimalarials | 2 | 2020 | 906 | 0.120 |
Why?
|
| Sodium, Dietary | 2 | 2017 | 425 | 0.120 |
Why?
|
| Sensitivity and Specificity | 8 | 2017 | 14660 | 0.120 |
Why?
|
| Bullying | 1 | 2018 | 221 | 0.120 |
Why?
|
| Safe Sex | 2 | 2020 | 139 | 0.120 |
Why?
|
| Equipment and Supplies | 1 | 2017 | 275 | 0.120 |
Why?
|
| Cholesterol, HDL | 4 | 2018 | 1817 | 0.120 |
Why?
|
| Health Systems Plans | 1 | 2014 | 19 | 0.120 |
Why?
|
| Growth | 2 | 2014 | 365 | 0.120 |
Why?
|
| Age Distribution | 9 | 2015 | 2893 | 0.120 |
Why?
|
| Professional-Patient Relations | 2 | 2018 | 726 | 0.120 |
Why?
|
| Environmental Monitoring | 4 | 2016 | 1441 | 0.120 |
Why?
|
| Infertility, Female | 4 | 2012 | 759 | 0.120 |
Why?
|
| Pregnant Women | 1 | 2019 | 563 | 0.120 |
Why?
|
| Health | 2 | 2015 | 396 | 0.120 |
Why?
|
| Phthalic Acids | 1 | 2019 | 476 | 0.120 |
Why?
|
| Prostatic Neoplasms | 4 | 2016 | 11345 | 0.120 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 861 | 0.120 |
Why?
|
| Parity | 5 | 2023 | 925 | 0.120 |
Why?
|
| Databases, Factual | 2 | 2021 | 8035 | 0.120 |
Why?
|
| Child Welfare | 2 | 2012 | 516 | 0.120 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 2020 | 2197 | 0.120 |
Why?
|
| Taste | 2 | 2013 | 188 | 0.120 |
Why?
|
| Urban Population | 4 | 2016 | 2022 | 0.120 |
Why?
|
| Mothers | 3 | 2019 | 2186 | 0.120 |
Why?
|
| Data Collection | 2 | 2022 | 3315 | 0.120 |
Why?
|
| Spouses | 1 | 2016 | 279 | 0.110 |
Why?
|
| Body Fat Distribution | 1 | 2015 | 243 | 0.110 |
Why?
|
| Xanthophylls | 2 | 2012 | 95 | 0.110 |
Why?
|
| Superoxide Dismutase | 2 | 2008 | 594 | 0.110 |
Why?
|
| Carbohydrates | 2 | 2015 | 388 | 0.110 |
Why?
|
| Prostaglandin Antagonists | 1 | 2013 | 28 | 0.110 |
Why?
|
| Family Planning Services | 1 | 2016 | 265 | 0.110 |
Why?
|
| Social Support | 3 | 2019 | 2145 | 0.110 |
Why?
|
| Health Plan Implementation | 1 | 2016 | 335 | 0.110 |
Why?
|
| Fabaceae | 1 | 2014 | 103 | 0.110 |
Why?
|
| Mental Health | 4 | 2024 | 3213 | 0.110 |
Why?
|
| Communicable Diseases | 1 | 2022 | 878 | 0.110 |
Why?
|
| Lutein | 2 | 2012 | 122 | 0.110 |
Why?
|
| Estrogens | 5 | 2011 | 1520 | 0.110 |
Why?
|
| Aged, 80 and over | 25 | 2021 | 58995 | 0.110 |
Why?
|
| Breast Diseases | 1 | 2016 | 443 | 0.110 |
Why?
|
| Contraception | 1 | 2016 | 349 | 0.110 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2016 | 4555 | 0.110 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2014 | 131 | 0.110 |
Why?
|
| Parasitemia | 2 | 2012 | 166 | 0.110 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 2 | 2012 | 159 | 0.110 |
Why?
|
| Checklist | 1 | 2020 | 827 | 0.110 |
Why?
|
| Patient Compliance | 3 | 2018 | 2688 | 0.110 |
Why?
|
| Wounds and Injuries | 2 | 2016 | 2477 | 0.100 |
Why?
|
| Health Transition | 1 | 2012 | 35 | 0.100 |
Why?
|
| Ovarian Neoplasms | 5 | 2008 | 4878 | 0.100 |
Why?
|
| Phenylpyruvic Acids | 1 | 2012 | 4 | 0.100 |
Why?
|
| Pre-Eclampsia | 1 | 2022 | 1229 | 0.100 |
Why?
|
| Pathology, Molecular | 1 | 2015 | 329 | 0.100 |
Why?
|
| Papillomavirus Vaccines | 1 | 2019 | 495 | 0.100 |
Why?
|
| Seeds | 1 | 2013 | 120 | 0.100 |
Why?
|
| Carbon | 1 | 2016 | 669 | 0.100 |
Why?
|
| Prejudice | 1 | 2016 | 563 | 0.100 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2022 | 1164 | 0.100 |
Why?
|
| Battered Women | 1 | 2012 | 36 | 0.100 |
Why?
|
| Catechols | 1 | 2012 | 62 | 0.100 |
Why?
|
| Multiple Sclerosis | 4 | 2010 | 3204 | 0.100 |
Why?
|
| Hodgkin Disease | 3 | 2004 | 1378 | 0.100 |
Why?
|
| Vitamin D Deficiency | 3 | 2011 | 1379 | 0.100 |
Why?
|
| Vaginal Smears | 1 | 2015 | 495 | 0.100 |
Why?
|
| Prenatal Diagnosis | 1 | 2019 | 1264 | 0.100 |
Why?
|
| Resorcinols | 1 | 2012 | 41 | 0.100 |
Why?
|
| Urbanization | 1 | 2012 | 100 | 0.100 |
Why?
|
| Psychomotor Disorders | 1 | 2012 | 149 | 0.100 |
Why?
|
| Uganda | 4 | 2020 | 1324 | 0.100 |
Why?
|
| Arsenic | 1 | 2015 | 357 | 0.100 |
Why?
|
| Minerals | 2 | 2005 | 283 | 0.100 |
Why?
|
| Feasibility Studies | 2 | 2020 | 5201 | 0.100 |
Why?
|
| Creatinine | 4 | 2019 | 1903 | 0.100 |
Why?
|
| Gestational Age | 3 | 2018 | 3565 | 0.100 |
Why?
|
| North America | 7 | 2010 | 1284 | 0.100 |
Why?
|
| Waist Circumference | 1 | 2015 | 926 | 0.100 |
Why?
|
| Mental Health Services | 1 | 2023 | 1717 | 0.100 |
Why?
|
| Delivery, Obstetric | 2 | 2016 | 932 | 0.100 |
Why?
|
| Water Pollutants, Chemical | 1 | 2015 | 354 | 0.100 |
Why?
|
| Hospitals | 2 | 2023 | 3928 | 0.100 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 2011 | 64 | 0.100 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2020 | 1903 | 0.100 |
Why?
|
| Diabetes Complications | 3 | 2015 | 1341 | 0.090 |
Why?
|
| Sex Offenses | 2 | 2012 | 351 | 0.090 |
Why?
|
| Efficiency, Organizational | 1 | 2016 | 697 | 0.090 |
Why?
|
| World Health Organization | 2 | 2014 | 1312 | 0.090 |
Why?
|
| Food Supply | 1 | 2017 | 542 | 0.090 |
Why?
|
| Hip Fractures | 2 | 2011 | 989 | 0.090 |
Why?
|
| Kidney Neoplasms | 4 | 2009 | 4312 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2010 | 2282 | 0.090 |
Why?
|
| South Africa | 3 | 2024 | 1821 | 0.090 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2017 | 1724 | 0.090 |
Why?
|
| Diarrhea, Infantile | 1 | 2011 | 101 | 0.090 |
Why?
|
| Progesterone | 2 | 2013 | 742 | 0.090 |
Why?
|
| Autistic Disorder | 2 | 2011 | 1216 | 0.090 |
Why?
|
| Menstrual Cycle | 3 | 2011 | 536 | 0.090 |
Why?
|
| Continuity of Patient Care | 1 | 2018 | 1066 | 0.090 |
Why?
|
| Infant Nutrition Disorders | 1 | 2011 | 70 | 0.090 |
Why?
|
| Cotinine | 1 | 2011 | 203 | 0.090 |
Why?
|
| Bone Density | 3 | 2009 | 3534 | 0.090 |
Why?
|
| Neoplasms | 8 | 2023 | 22072 | 0.090 |
Why?
|
| Haplotypes | 3 | 2006 | 2764 | 0.090 |
Why?
|
| Europe | 8 | 2010 | 3441 | 0.090 |
Why?
|
| Chronobiology Disorders | 1 | 2011 | 72 | 0.090 |
Why?
|
| Mongolia | 2 | 2022 | 93 | 0.090 |
Why?
|
| Attitude to Health | 3 | 2011 | 2029 | 0.090 |
Why?
|
| Ovulation Induction | 1 | 2012 | 277 | 0.090 |
Why?
|
| Tooth Loss | 1 | 2012 | 198 | 0.090 |
Why?
|
| Disease | 1 | 2015 | 671 | 0.090 |
Why?
|
| Diagnostic Errors | 1 | 2017 | 1266 | 0.090 |
Why?
|
| Predictive Value of Tests | 9 | 2015 | 15289 | 0.090 |
Why?
|
| Residence Characteristics | 2 | 2016 | 2062 | 0.090 |
Why?
|
| Dichlorodiphenyl Dichloroethylene | 1 | 2010 | 85 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2019 | 3164 | 0.090 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2011 | 662 | 0.090 |
Why?
|
| Respiratory Tract Diseases | 1 | 2015 | 748 | 0.090 |
Why?
|
| Sunlight | 1 | 2011 | 337 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 5 | 2017 | 6068 | 0.080 |
Why?
|
| Monte Carlo Method | 1 | 2015 | 1257 | 0.080 |
Why?
|
| Lipogenesis | 1 | 2011 | 210 | 0.080 |
Why?
|
| Maternal Age | 4 | 2014 | 807 | 0.080 |
Why?
|
| Quality Improvement | 2 | 2015 | 3836 | 0.080 |
Why?
|
| Sexual Partners | 4 | 2019 | 753 | 0.080 |
Why?
|
| Estradiol | 3 | 2013 | 1932 | 0.080 |
Why?
|
| DNA Methylation | 4 | 2012 | 4373 | 0.080 |
Why?
|
| Androgens | 3 | 2013 | 1291 | 0.080 |
Why?
|
| Interleukin-6 | 3 | 2018 | 3215 | 0.080 |
Why?
|
| Absorptiometry, Photon | 3 | 2010 | 1736 | 0.080 |
Why?
|
| Comorbidity | 9 | 2015 | 10551 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 3 | 2017 | 5508 | 0.080 |
Why?
|
| Peptic Ulcer | 2 | 2009 | 219 | 0.080 |
Why?
|
| Occupational Health | 2 | 2024 | 805 | 0.080 |
Why?
|
| Ambulatory Care Facilities | 1 | 2015 | 926 | 0.080 |
Why?
|
| C-Reactive Protein | 4 | 2018 | 3839 | 0.080 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2016 | 951 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 11712 | 0.080 |
Why?
|
| Polymorphism, Genetic | 5 | 2007 | 4291 | 0.080 |
Why?
|
| Periodontal Diseases | 1 | 2012 | 452 | 0.080 |
Why?
|
| Netherlands | 2 | 2015 | 2213 | 0.080 |
Why?
|
| Plant Proteins | 1 | 2010 | 370 | 0.080 |
Why?
|
| Dietary Sucrose | 1 | 2010 | 244 | 0.080 |
Why?
|
| Health Planning | 1 | 2009 | 232 | 0.080 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2011 | 261 | 0.080 |
Why?
|
| Sulfur Dioxide | 1 | 2008 | 177 | 0.080 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2010 | 235 | 0.070 |
Why?
|
| Lipids | 2 | 2013 | 3336 | 0.070 |
Why?
|
| Placenta | 1 | 2017 | 1702 | 0.070 |
Why?
|
| Hepatitis B | 1 | 2013 | 701 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2023 | 3426 | 0.070 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 3696 | 0.070 |
Why?
|
| Dietary Fats, Unsaturated | 2 | 2008 | 225 | 0.070 |
Why?
|
| Ferritins | 3 | 2016 | 597 | 0.070 |
Why?
|
| Myocardial Ischemia | 2 | 2010 | 2164 | 0.070 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2002 | 559 | 0.070 |
Why?
|
| Walking | 1 | 2014 | 1189 | 0.070 |
Why?
|
| Soot | 1 | 2008 | 221 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2013 | 2864 | 0.070 |
Why?
|
| Ultraviolet Rays | 1 | 2011 | 1078 | 0.070 |
Why?
|
| Vaccination | 1 | 2019 | 3361 | 0.070 |
Why?
|
| Caffeine | 3 | 2010 | 702 | 0.070 |
Why?
|
| Calcifediol | 1 | 2007 | 161 | 0.070 |
Why?
|
| Violence | 1 | 2012 | 927 | 0.070 |
Why?
|
| Prognosis | 11 | 2022 | 29658 | 0.070 |
Why?
|
| Medicaid | 1 | 2020 | 2815 | 0.070 |
Why?
|
| Parkinson Disease | 2 | 2010 | 2859 | 0.070 |
Why?
|
| Cholesterol | 3 | 2018 | 2924 | 0.070 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2011 | 1572 | 0.070 |
Why?
|
| Sulfites | 1 | 2006 | 83 | 0.070 |
Why?
|
| Lactose | 1 | 2006 | 95 | 0.070 |
Why?
|
| Sex Distribution | 5 | 2015 | 2295 | 0.070 |
Why?
|
| Particle Size | 3 | 2015 | 1644 | 0.070 |
Why?
|
| Eicosanoic Acids | 2 | 2015 | 15 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2016 | 17790 | 0.060 |
Why?
|
| Skin Diseases | 1 | 2014 | 1089 | 0.060 |
Why?
|
| Acetaminophen | 2 | 2009 | 553 | 0.060 |
Why?
|
| Hair Color | 1 | 2006 | 131 | 0.060 |
Why?
|
| Drug Residues | 1 | 2005 | 7 | 0.060 |
Why?
|
| Fertility | 2 | 2012 | 773 | 0.060 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2009 | 586 | 0.060 |
Why?
|
| Oxandrolone | 1 | 2005 | 24 | 0.060 |
Why?
|
| Cost of Illness | 1 | 2015 | 1940 | 0.060 |
Why?
|
| Genes | 1 | 2009 | 1845 | 0.060 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2006 | 240 | 0.060 |
Why?
|
| Tocopherols | 1 | 2005 | 44 | 0.060 |
Why?
|
| Stearic Acids | 2 | 2015 | 56 | 0.060 |
Why?
|
| Lipoproteins, HDL | 2 | 2011 | 667 | 0.060 |
Why?
|
| RNA, Viral | 2 | 2004 | 2838 | 0.060 |
Why?
|
| Hyperglycemia | 1 | 2014 | 1380 | 0.060 |
Why?
|
| Dehydroepiandrosterone | 1 | 2006 | 257 | 0.060 |
Why?
|
| Flavonols | 1 | 2005 | 83 | 0.060 |
Why?
|
| Muscle, Skeletal | 2 | 2018 | 4925 | 0.060 |
Why?
|
| Sex Characteristics | 7 | 2015 | 2629 | 0.060 |
Why?
|
| Disease Progression | 8 | 2022 | 13502 | 0.060 |
Why?
|
| Physical Education and Training | 1 | 2005 | 100 | 0.060 |
Why?
|
| Drug Therapy, Combination | 5 | 2020 | 6498 | 0.060 |
Why?
|
| Insulin | 2 | 2014 | 6597 | 0.060 |
Why?
|
| Receptors, Calcitriol | 1 | 2007 | 359 | 0.060 |
Why?
|
| Diethylstilbestrol | 1 | 2004 | 88 | 0.060 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2004 | 52 | 0.060 |
Why?
|
| Atrial Fibrillation | 2 | 2014 | 5209 | 0.060 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2005 | 113 | 0.060 |
Why?
|
| Maternal Mortality | 2 | 2020 | 300 | 0.060 |
Why?
|
| Palmitic Acid | 2 | 2015 | 149 | 0.060 |
Why?
|
| Mutation | 6 | 2013 | 29932 | 0.060 |
Why?
|
| Resins, Plant | 1 | 1984 | 20 | 0.060 |
Why?
|
| Quality Indicators, Health Care | 1 | 2014 | 1824 | 0.060 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 2024 | 105 | 0.060 |
Why?
|
| Uric Acid | 1 | 2010 | 806 | 0.060 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2005 | 138 | 0.060 |
Why?
|
| Colonoscopy | 1 | 2012 | 1387 | 0.060 |
Why?
|
| Adenoma | 2 | 2013 | 2148 | 0.060 |
Why?
|
| Pregnancy Trimester, Second | 4 | 2011 | 732 | 0.060 |
Why?
|
| Microsatellite Instability | 3 | 2013 | 715 | 0.060 |
Why?
|
| Pregnancy, Multiple | 1 | 2004 | 215 | 0.060 |
Why?
|
| Least-Squares Analysis | 1 | 2004 | 369 | 0.060 |
Why?
|
| Boston | 6 | 2008 | 9280 | 0.060 |
Why?
|
| Follicular Phase | 1 | 2004 | 143 | 0.060 |
Why?
|
| Luteal Phase | 1 | 2004 | 138 | 0.050 |
Why?
|
| Sputum | 2 | 2017 | 503 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 9276 | 0.050 |
Why?
|
| Minisatellite Repeats | 1 | 2003 | 164 | 0.050 |
Why?
|
| Interleukin-1 | 2 | 2004 | 1249 | 0.050 |
Why?
|
| Trans Fatty Acids | 1 | 2004 | 155 | 0.050 |
Why?
|
| Pneumoconiosis | 1 | 1982 | 32 | 0.050 |
Why?
|
| Inhalation Exposure | 1 | 2006 | 429 | 0.050 |
Why?
|
| Tandem Repeat Sequences | 1 | 2003 | 180 | 0.050 |
Why?
|
| Organophosphorus Compounds | 1 | 1984 | 202 | 0.050 |
Why?
|
| Rubber | 1 | 1982 | 47 | 0.050 |
Why?
|
| Antidepressive Agents | 1 | 2015 | 2890 | 0.050 |
Why?
|
| Costa Rica | 4 | 2003 | 177 | 0.050 |
Why?
|
| Severity of Illness Index | 7 | 2015 | 15840 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 3865 | 0.050 |
Why?
|
| Lipodystrophy | 1 | 2003 | 148 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2010 | 2773 | 0.050 |
Why?
|
| Electronics | 1 | 1984 | 315 | 0.050 |
Why?
|
| Hepacivirus | 1 | 2009 | 1334 | 0.050 |
Why?
|
| Menstruation | 1 | 2004 | 307 | 0.050 |
Why?
|
| gamma-Tocopherol | 1 | 2002 | 30 | 0.050 |
Why?
|
| Vitamin B 6 | 1 | 2003 | 233 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2013 | 6544 | 0.050 |
Why?
|
| Public Housing | 1 | 2023 | 140 | 0.050 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2004 | 364 | 0.050 |
Why?
|
| Alabama | 1 | 2022 | 104 | 0.050 |
Why?
|
| Pneumonia | 1 | 2013 | 2131 | 0.050 |
Why?
|
| Immunoglobulin E | 1 | 2008 | 1484 | 0.050 |
Why?
|
| Genotype | 7 | 2019 | 12960 | 0.050 |
Why?
|
| Food Analysis | 1 | 2002 | 103 | 0.050 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 3 | 2010 | 157 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2014 | 3598 | 0.050 |
Why?
|
| Aromatase | 1 | 2002 | 147 | 0.050 |
Why?
|
| Colitis, Ulcerative | 1 | 2013 | 1919 | 0.050 |
Why?
|
| Pandemics | 1 | 2021 | 8624 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2017 | 15789 | 0.050 |
Why?
|
| Contraceptives, Oral | 1 | 2004 | 554 | 0.050 |
Why?
|
| Air Pollutants, Occupational | 1 | 1984 | 407 | 0.050 |
Why?
|
| Ovulation | 1 | 2002 | 181 | 0.050 |
Why?
|
| Nitrogen | 2 | 2014 | 350 | 0.050 |
Why?
|
| Human T-lymphotropic virus 1 | 2 | 1998 | 142 | 0.050 |
Why?
|
| Cholelithiasis | 1 | 2002 | 408 | 0.050 |
Why?
|
| Peripheral Arterial Disease | 1 | 2012 | 1306 | 0.050 |
Why?
|
| Qualitative Research | 2 | 2024 | 2963 | 0.050 |
Why?
|
| Genes, ras | 1 | 2003 | 655 | 0.050 |
Why?
|
| Reference Values | 4 | 2013 | 4925 | 0.050 |
Why?
|
| Crohn Disease | 1 | 2013 | 2275 | 0.050 |
Why?
|
| Population Surveillance | 5 | 2016 | 2608 | 0.050 |
Why?
|
| Medical Assistance | 1 | 2021 | 107 | 0.050 |
Why?
|
| Leucovorin | 2 | 2013 | 641 | 0.050 |
Why?
|
| United Nations | 1 | 2021 | 151 | 0.050 |
Why?
|
| Survivors | 2 | 2008 | 2375 | 0.050 |
Why?
|
| Parturition | 2 | 2020 | 446 | 0.040 |
Why?
|
| Aging | 4 | 2016 | 8651 | 0.040 |
Why?
|
| Vitamin B 12 | 1 | 2003 | 522 | 0.040 |
Why?
|
| Genome, Viral | 1 | 2004 | 658 | 0.040 |
Why?
|
| Coal | 1 | 2020 | 119 | 0.040 |
Why?
|
| China | 2 | 2020 | 2339 | 0.040 |
Why?
|
| Alleles | 3 | 2006 | 6898 | 0.040 |
Why?
|
| Ethiopia | 1 | 2022 | 462 | 0.040 |
Why?
|
| Length of Stay | 1 | 2013 | 6479 | 0.040 |
Why?
|
| Tuberculin Test | 1 | 2020 | 206 | 0.040 |
Why?
|
| Perinatal Mortality | 1 | 2020 | 101 | 0.040 |
Why?
|
| Zambia | 1 | 2020 | 257 | 0.040 |
Why?
|
| Employee Performance Appraisal | 1 | 2020 | 86 | 0.040 |
Why?
|
| Homocysteine | 1 | 2002 | 640 | 0.040 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2003 | 752 | 0.040 |
Why?
|
| Hepatitis C | 1 | 2009 | 1579 | 0.040 |
Why?
|
| Schools | 1 | 2008 | 1480 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2017 | 4899 | 0.040 |
Why?
|
| Social Environment | 1 | 2004 | 1022 | 0.040 |
Why?
|
| Microbiological Techniques | 1 | 2020 | 98 | 0.040 |
Why?
|
| Camptothecin | 2 | 2013 | 590 | 0.040 |
Why?
|
| Government Programs | 1 | 2021 | 280 | 0.040 |
Why?
|
| Lipoproteins | 1 | 2004 | 882 | 0.040 |
Why?
|
| Colposcopy | 1 | 2019 | 150 | 0.040 |
Why?
|
| Islam | 1 | 2019 | 71 | 0.040 |
Why?
|
| Skin Neoplasms | 3 | 2003 | 5799 | 0.040 |
Why?
|
| Statistics, Nonparametric | 4 | 2006 | 2852 | 0.040 |
Why?
|
| Menopause | 3 | 2016 | 1640 | 0.040 |
Why?
|
| Cross-Over Studies | 2 | 2015 | 2061 | 0.040 |
Why?
|
| HTLV-I Infections | 1 | 1998 | 103 | 0.040 |
Why?
|
| Anacardium | 1 | 2018 | 6 | 0.040 |
Why?
|
| Social Class | 3 | 2014 | 2005 | 0.040 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2006 | 1928 | 0.040 |
Why?
|
| Leukemia, T-Cell | 1 | 1998 | 101 | 0.040 |
Why?
|
| Prostate-Specific Antigen | 1 | 2008 | 2529 | 0.040 |
Why?
|
| Carrier State | 2 | 1998 | 525 | 0.040 |
Why?
|
| Kidney | 2 | 2004 | 7064 | 0.040 |
Why?
|
| Namibia | 1 | 2017 | 26 | 0.040 |
Why?
|
| Patient Satisfaction | 2 | 2017 | 3448 | 0.040 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 1998 | 164 | 0.040 |
Why?
|
| Fluorouracil | 2 | 2013 | 1631 | 0.040 |
Why?
|
| Obstetric Labor Complications | 1 | 2020 | 236 | 0.040 |
Why?
|
| Transients and Migrants | 1 | 2020 | 162 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2013 | 8555 | 0.040 |
Why?
|
| Inservice Training | 1 | 2020 | 375 | 0.040 |
Why?
|
| Restaurants | 1 | 2020 | 230 | 0.040 |
Why?
|
| Abdomen | 1 | 2003 | 1130 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2013 | 895 | 0.040 |
Why?
|
| Heart Failure | 2 | 2012 | 11847 | 0.040 |
Why?
|
| HIV | 2 | 2020 | 1579 | 0.040 |
Why?
|
| Infant, Premature | 3 | 2014 | 2092 | 0.040 |
Why?
|
| Models, Biological | 2 | 2011 | 9467 | 0.040 |
Why?
|
| Ethanol | 1 | 2003 | 1323 | 0.040 |
Why?
|
| Seasons | 4 | 2010 | 1522 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2008 | 2093 | 0.040 |
Why?
|
| Puerperal Disorders | 1 | 2020 | 300 | 0.040 |
Why?
|
| Antineoplastic Agents | 3 | 2024 | 13630 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2003 | 820 | 0.040 |
Why?
|
| Food Contamination | 2 | 2011 | 192 | 0.040 |
Why?
|
| Senegal | 1 | 2017 | 256 | 0.030 |
Why?
|
| Triglycerides | 2 | 2018 | 2476 | 0.030 |
Why?
|
| Allergens | 2 | 2001 | 1402 | 0.030 |
Why?
|
| Sri Lanka | 1 | 2016 | 92 | 0.030 |
Why?
|
| Hospitalization | 1 | 2016 | 10790 | 0.030 |
Why?
|
| Retrospective Studies | 9 | 2022 | 80372 | 0.030 |
Why?
|
| Awareness | 2 | 2011 | 646 | 0.030 |
Why?
|
| Standard of Care | 1 | 2020 | 552 | 0.030 |
Why?
|
| Stress, Psychological | 2 | 2015 | 4446 | 0.030 |
Why?
|
| Malawi | 1 | 2017 | 301 | 0.030 |
Why?
|
| Value of Life | 1 | 2016 | 98 | 0.030 |
Why?
|
| Nutrition Disorders | 1 | 1997 | 205 | 0.030 |
Why?
|
| Educational Status | 2 | 2015 | 2515 | 0.030 |
Why?
|
| Infant Food | 1 | 2016 | 140 | 0.030 |
Why?
|
| Placebos | 2 | 2012 | 1668 | 0.030 |
Why?
|
| ras Proteins | 2 | 2013 | 1052 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2018 | 346 | 0.030 |
Why?
|
| Protoporphyrins | 1 | 2016 | 165 | 0.030 |
Why?
|
| Pregnancy Trimester, First | 2 | 2011 | 908 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 2002 | 1077 | 0.030 |
Why?
|
| Central Nervous System Stimulants | 1 | 2004 | 1174 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2008 | 4353 | 0.030 |
Why?
|
| Haiti | 1 | 2017 | 549 | 0.030 |
Why?
|
| Bangladesh | 1 | 2017 | 728 | 0.030 |
Why?
|
| Electric Impedance | 3 | 2006 | 755 | 0.030 |
Why?
|
| Peripartum Period | 1 | 2016 | 138 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2004 | 2488 | 0.030 |
Why?
|
| Medical History Taking | 2 | 2012 | 773 | 0.030 |
Why?
|
| Animals | 15 | 2013 | 167963 | 0.030 |
Why?
|
| Rwanda | 1 | 2017 | 659 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 7408 | 0.030 |
Why?
|
| Rhode Island | 2 | 2008 | 349 | 0.030 |
Why?
|
| Capacity Building | 1 | 2017 | 257 | 0.030 |
Why?
|
| Vascular Diseases | 1 | 2003 | 1182 | 0.030 |
Why?
|
| Cystatin C | 2 | 2008 | 270 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 6315 | 0.030 |
Why?
|
| Estrone | 2 | 2011 | 232 | 0.030 |
Why?
|
| Receptors, Transferrin | 1 | 2016 | 291 | 0.030 |
Why?
|
| Opportunistic Infections | 1 | 2017 | 377 | 0.030 |
Why?
|
| Respiratory Function Tests | 2 | 2013 | 1683 | 0.030 |
Why?
|
| Hospitals, Urban | 1 | 2016 | 499 | 0.030 |
Why?
|
| Organizational Policy | 1 | 2016 | 429 | 0.030 |
Why?
|
| Alkynes | 1 | 2015 | 313 | 0.030 |
Why?
|
| Zinc Sulfate | 1 | 2013 | 18 | 0.030 |
Why?
|
| Life Change Events | 2 | 2010 | 952 | 0.030 |
Why?
|
| Phenotype | 2 | 2009 | 16546 | 0.030 |
Why?
|
| Glutathione Transferase | 1 | 2016 | 565 | 0.030 |
Why?
|
| Behavior Therapy | 1 | 2019 | 868 | 0.030 |
Why?
|
| Nevirapine | 1 | 2015 | 273 | 0.030 |
Why?
|
| Capsid Proteins | 2 | 2010 | 467 | 0.030 |
Why?
|
| Amenorrhea | 1 | 2017 | 480 | 0.030 |
Why?
|
| Binomial Distribution | 1 | 2013 | 23 | 0.030 |
Why?
|
| Neoplasm Staging | 3 | 2013 | 11152 | 0.030 |
Why?
|
| Ovariectomy | 1 | 2016 | 611 | 0.030 |
Why?
|
| Patient Participation | 1 | 2003 | 1439 | 0.030 |
Why?
|
| Lamivudine | 1 | 2015 | 363 | 0.030 |
Why?
|
| Cyclopropanes | 1 | 2015 | 431 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2013 | 1728 | 0.030 |
Why?
|
| Benzoxazines | 1 | 2015 | 309 | 0.030 |
Why?
|
| Testosterone | 2 | 2002 | 2470 | 0.030 |
Why?
|
| Smoke | 1 | 2015 | 236 | 0.030 |
Why?
|
| Placenta Diseases | 1 | 2015 | 196 | 0.030 |
Why?
|
| United States Environmental Protection Agency | 1 | 2013 | 139 | 0.030 |
Why?
|
| Antigens, Viral | 2 | 2010 | 980 | 0.030 |
Why?
|
| Recurrence | 2 | 2018 | 8482 | 0.030 |
Why?
|
| Zidovudine | 1 | 2015 | 624 | 0.030 |
Why?
|
| Psychometrics | 1 | 2023 | 3051 | 0.030 |
Why?
|
| House Calls | 1 | 2014 | 160 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2004 | 3106 | 0.030 |
Why?
|
| Sulfates | 1 | 2014 | 379 | 0.030 |
Why?
|
| Detergents | 1 | 2013 | 235 | 0.030 |
Why?
|
| Neutron Activation Analysis | 1 | 2012 | 35 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 2013 | 866 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 2014 | 1628 | 0.030 |
Why?
|
| Obesity, Abdominal | 1 | 2015 | 374 | 0.030 |
Why?
|
| Drug Resistance, Viral | 1 | 2017 | 859 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 6828 | 0.030 |
Why?
|
| DNA | 1 | 2006 | 7233 | 0.030 |
Why?
|
| Estriol | 1 | 2011 | 51 | 0.030 |
Why?
|
| Fatty Acid Desaturases | 1 | 2012 | 102 | 0.030 |
Why?
|
| Angina Pectoris | 1 | 2016 | 969 | 0.020 |
Why?
|
| Social Stigma | 1 | 2018 | 734 | 0.020 |
Why?
|
| Chemistry, Clinical | 1 | 2012 | 64 | 0.020 |
Why?
|
| Candidiasis, Oral | 1 | 2011 | 57 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2003 | 2064 | 0.020 |
Why?
|
| Latin America | 1 | 2013 | 404 | 0.020 |
Why?
|
| Cholesterol, LDL | 3 | 2009 | 2420 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2005 | 3959 | 0.020 |
Why?
|
| Stavudine | 1 | 2011 | 84 | 0.020 |
Why?
|
| Lactation | 2 | 2004 | 397 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2008 | 4371 | 0.020 |
Why?
|
| Asia | 1 | 2013 | 620 | 0.020 |
Why?
|
| Minority Groups | 2 | 2013 | 1201 | 0.020 |
Why?
|
| Cities | 1 | 2014 | 538 | 0.020 |
Why?
|
| Culture | 1 | 2015 | 622 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 2004 | 3726 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 1677 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2013 | 412 | 0.020 |
Why?
|
| X-Rays | 1 | 2011 | 307 | 0.020 |
Why?
|
| Infant Welfare | 1 | 2011 | 80 | 0.020 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 8056 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2013 | 599 | 0.020 |
Why?
|
| Massachusetts | 4 | 2005 | 8803 | 0.020 |
Why?
|
| Africa | 1 | 2013 | 705 | 0.020 |
Why?
|
| Immunoglobulin A | 2 | 2005 | 979 | 0.020 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2014 | 457 | 0.020 |
Why?
|
| Coronary Artery Disease | 2 | 2016 | 6659 | 0.020 |
Why?
|
| Trauma Severity Indices | 1 | 2012 | 478 | 0.020 |
Why?
|
| Appointments and Schedules | 1 | 2014 | 442 | 0.020 |
Why?
|
| Disinfectants | 1 | 2011 | 130 | 0.020 |
Why?
|
| Lymphocytes | 1 | 1998 | 2611 | 0.020 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2003 | 582 | 0.020 |
Why?
|
| Hysterectomy | 1 | 2016 | 904 | 0.020 |
Why?
|
| Gene Frequency | 2 | 2009 | 3615 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2017 | 2435 | 0.020 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2016 | 1206 | 0.020 |
Why?
|
| Plant Oils | 1 | 2011 | 197 | 0.020 |
Why?
|
| Needle Sharing | 1 | 2009 | 22 | 0.020 |
Why?
|
| Iron Overload | 1 | 2012 | 240 | 0.020 |
Why?
|
| Humidity | 2 | 2001 | 205 | 0.020 |
Why?
|
| Bottle Feeding | 1 | 2010 | 67 | 0.020 |
Why?
|
| New South Wales | 1 | 2009 | 70 | 0.020 |
Why?
|
| Cattle | 2 | 2006 | 3847 | 0.020 |
Why?
|
| Receptor, erbB-2 | 1 | 2020 | 2554 | 0.020 |
Why?
|
| Fetal Hypoxia | 1 | 2009 | 30 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 2004 | 9585 | 0.020 |
Why?
|
| Syringes | 1 | 2009 | 57 | 0.020 |
Why?
|
| Internationality | 1 | 2015 | 1004 | 0.020 |
Why?
|
| Developed Countries | 1 | 2012 | 442 | 0.020 |
Why?
|
| Maternal Welfare | 1 | 2010 | 112 | 0.020 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2009 | 52 | 0.020 |
Why?
|
| Postpartum Period | 1 | 2016 | 1167 | 0.020 |
Why?
|
| Plasmodium | 1 | 2012 | 247 | 0.020 |
Why?
|
| HTLV-I Antibodies | 2 | 1998 | 35 | 0.020 |
Why?
|
| Birth Order | 1 | 2009 | 95 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2013 | 4490 | 0.020 |
Why?
|
| Health Occupations | 1 | 2010 | 222 | 0.020 |
Why?
|
| Species Specificity | 1 | 2013 | 2418 | 0.020 |
Why?
|
| Drug Interactions | 2 | 2003 | 1428 | 0.020 |
Why?
|
| Cholesterol, Dietary | 1 | 2008 | 223 | 0.020 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2011 | 542 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 2011 | 641 | 0.020 |
Why?
|
| Maternal Behavior | 1 | 2010 | 306 | 0.020 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2009 | 190 | 0.020 |
Why?
|
| Brain Ischemia | 2 | 2014 | 3127 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2011 | 987 | 0.020 |
Why?
|
| New Mexico | 1 | 2007 | 83 | 0.020 |
Why?
|
| Hip | 1 | 2009 | 251 | 0.020 |
Why?
|
| Caregivers | 1 | 2020 | 2224 | 0.020 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2012 | 497 | 0.020 |
Why?
|
| Sweetening Agents | 1 | 2010 | 290 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2015 | 4035 | 0.020 |
Why?
|
| Probability | 2 | 2003 | 2475 | 0.020 |
Why?
|
| Dyspepsia | 1 | 1988 | 118 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2011 | 1895 | 0.020 |
Why?
|
| Cytokines | 1 | 2002 | 7343 | 0.020 |
Why?
|
| Glucose Intolerance | 1 | 2011 | 580 | 0.020 |
Why?
|
| Genetic Variation | 2 | 2018 | 6551 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2003 | 4024 | 0.020 |
Why?
|
| Heroin Dependence | 1 | 2008 | 172 | 0.020 |
Why?
|
| Mining | 1 | 2007 | 91 | 0.020 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2011 | 613 | 0.020 |
Why?
|
| Neonatal Screening | 1 | 2011 | 595 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2018 | 2781 | 0.020 |
Why?
|
| Brain | 1 | 2013 | 26951 | 0.020 |
Why?
|
| Anesthetics, Inhalation | 1 | 2011 | 574 | 0.020 |
Why?
|
| Coronary Artery Bypass | 1 | 2016 | 2272 | 0.020 |
Why?
|
| Milk, Human | 1 | 2011 | 483 | 0.020 |
Why?
|
| Emigration and Immigration | 1 | 2009 | 395 | 0.020 |
Why?
|
| alpha-Tocopherol | 1 | 2006 | 126 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 36290 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2008 | 780 | 0.020 |
Why?
|
| Parents | 2 | 2010 | 3549 | 0.020 |
Why?
|
| Collagen Type II | 1 | 2006 | 148 | 0.020 |
Why?
|
| Kaempferols | 1 | 2005 | 21 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2011 | 1189 | 0.020 |
Why?
|
| Public Policy | 1 | 2009 | 560 | 0.020 |
Why?
|
| Ovarian Follicle | 1 | 2006 | 244 | 0.020 |
Why?
|
| Perception | 1 | 2011 | 1195 | 0.020 |
Why?
|
| Nicotine | 1 | 2010 | 677 | 0.020 |
Why?
|
| Patient Selection | 2 | 2010 | 4283 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 3465 | 0.020 |
Why?
|
| Genome-Wide Association Study | 2 | 2018 | 12626 | 0.020 |
Why?
|
| Quercetin | 1 | 2005 | 97 | 0.010 |
Why?
|
| Inflammation | 2 | 2017 | 10756 | 0.010 |
Why?
|
| Hormone Replacement Therapy | 1 | 2010 | 755 | 0.010 |
Why?
|
| Docosahexaenoic Acids | 1 | 2011 | 912 | 0.010 |
Why?
|
| Cocaine-Related Disorders | 1 | 2008 | 460 | 0.010 |
Why?
|
| Anxiety | 1 | 2019 | 4538 | 0.010 |
Why?
|
| Biopsy | 1 | 2016 | 6771 | 0.010 |
Why?
|
| Adaptation, Physiological | 1 | 2011 | 1296 | 0.010 |
Why?
|
| Insurance, Health | 1 | 2016 | 2501 | 0.010 |
Why?
|
| Body Constitution | 1 | 2004 | 273 | 0.010 |
Why?
|
| Progesterone Congeners | 1 | 2004 | 44 | 0.010 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2006 | 415 | 0.010 |
Why?
|
| Japan | 2 | 1998 | 1369 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2021 | 4647 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2013 | 4122 | 0.010 |
Why?
|
| Crime Victims | 1 | 2008 | 328 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2017 | 3258 | 0.010 |
Why?
|
| Hospital Records | 1 | 2004 | 93 | 0.010 |
Why?
|
| beta Catenin | 1 | 2009 | 1043 | 0.010 |
Why?
|
| Stents | 1 | 2016 | 3314 | 0.010 |
Why?
|
| Connecticut | 1 | 2004 | 365 | 0.010 |
Why?
|
| Ataxia Telangiectasia | 1 | 2004 | 107 | 0.010 |
Why?
|
| Temperance | 1 | 2003 | 87 | 0.010 |
Why?
|
| Gases | 1 | 1984 | 203 | 0.010 |
Why?
|
| Solar System | 1 | 2002 | 12 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2006 | 698 | 0.010 |
Why?
|
| Valine | 1 | 2004 | 409 | 0.010 |
Why?
|
| Anabolic Agents | 1 | 2005 | 253 | 0.010 |
Why?
|
| Beer | 1 | 2002 | 134 | 0.010 |
Why?
|
| Cholesterol, VLDL | 1 | 2002 | 71 | 0.010 |
Why?
|
| Maternal Exposure | 1 | 2009 | 1045 | 0.010 |
Why?
|
| Immunoglobulin G | 2 | 2005 | 4541 | 0.010 |
Why?
|
| Acute Disease | 1 | 2013 | 7269 | 0.010 |
Why?
|
| Selection Bias | 1 | 2004 | 358 | 0.010 |
Why?
|
| Wine | 1 | 2002 | 167 | 0.010 |
Why?
|
| Flavonoids | 1 | 2005 | 445 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2011 | 2828 | 0.010 |
Why?
|
| Animals, Domestic | 1 | 2001 | 57 | 0.010 |
Why?
|
| Quality of Life | 3 | 2012 | 13308 | 0.010 |
Why?
|
| Alanine | 1 | 2004 | 606 | 0.010 |
Why?
|
| Cadmium | 1 | 2002 | 215 | 0.010 |
Why?
|
| Dentists | 1 | 2002 | 176 | 0.010 |
Why?
|
| Autoimmunity | 1 | 2009 | 1370 | 0.010 |
Why?
|
| Chemoprevention | 1 | 2003 | 326 | 0.010 |
Why?
|
| Hormones | 1 | 2005 | 867 | 0.010 |
Why?
|
| Phytotherapy | 1 | 2003 | 295 | 0.010 |
Why?
|
| Cholecystectomy | 1 | 2002 | 406 | 0.010 |
Why?
|
| Industry | 1 | 1982 | 361 | 0.010 |
Why?
|
| Health Status Disparities | 1 | 2012 | 1830 | 0.010 |
Why?
|
| Cats | 1 | 2001 | 976 | 0.010 |
Why?
|
| Climate | 1 | 2000 | 147 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2002 | 783 | 0.010 |
Why?
|
| Vital Capacity | 1 | 1982 | 965 | 0.010 |
Why?
|
| Demography | 1 | 2004 | 1650 | 0.010 |
Why?
|
| Diabetes, Gestational | 1 | 2009 | 1242 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2012 | 3758 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2011 | 3061 | 0.010 |
Why?
|
| Gene Products, tax | 1 | 1998 | 51 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2009 | 2919 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 2003 | 755 | 0.010 |
Why?
|
| Arteries | 1 | 2003 | 1126 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2003 | 1745 | 0.010 |
Why?
|
| Food | 1 | 2003 | 771 | 0.010 |
Why?
|
| Abortion, Induced | 1 | 2004 | 460 | 0.010 |
Why?
|
| Random Allocation | 1 | 2002 | 2394 | 0.010 |
Why?
|
| Environmental Health | 1 | 2000 | 284 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2009 | 4713 | 0.010 |
Why?
|
| Diet, Reducing | 1 | 2001 | 488 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2007 | 2414 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 5785 | 0.010 |
Why?
|
| Registries | 2 | 2004 | 8469 | 0.010 |
Why?
|
| Employment | 1 | 2004 | 1112 | 0.010 |
Why?
|
| Rest | 1 | 2002 | 914 | 0.010 |
Why?
|
| Forced Expiratory Volume | 1 | 1982 | 1809 | 0.010 |
Why?
|
| Sudan | 1 | 1997 | 86 | 0.010 |
Why?
|
| Cognition | 1 | 2014 | 6957 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 2007 | 2061 | 0.010 |
Why?
|
| Eye Diseases | 1 | 1982 | 651 | 0.010 |
Why?
|
| Fasting | 1 | 2003 | 1603 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2002 | 2025 | 0.010 |
Why?
|
| Dogs | 1 | 2001 | 3841 | 0.010 |
Why?
|
| ROC Curve | 1 | 2004 | 3568 | 0.010 |
Why?
|
| Military Personnel | 1 | 2005 | 1244 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 2895 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 11071 | 0.010 |
Why?
|
| Carcinoma | 1 | 2006 | 2331 | 0.010 |
Why?
|
| Androstenedione | 1 | 1994 | 131 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 2003 | 2180 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2004 | 2802 | 0.010 |
Why?
|
| Gene Expression | 1 | 2006 | 7588 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2006 | 4938 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2004 | 3446 | 0.010 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2007 | 3224 | 0.010 |
Why?
|
| Asthma | 2 | 2001 | 6172 | 0.010 |
Why?
|
| Hypersensitivity | 1 | 2001 | 1155 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 5791 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 4357 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 1998 | 1347 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2006 | 8515 | 0.010 |
Why?
|
| Cimetidine | 1 | 1988 | 76 | 0.000 |
Why?
|
| Antacids | 1 | 1988 | 94 | 0.000 |
Why?
|
| Health Maintenance Organizations | 1 | 1988 | 660 | 0.000 |
Why?
|
| Analgesics | 1 | 1988 | 1065 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 1998 | 10181 | 0.000 |
Why?
|
| Mice | 1 | 2001 | 81208 | 0.000 |
Why?
|